Open AccessManagement of Pulmonary Hypertension Due to Chronic Lung Disease
Author(s) -
Jordan Sugarman,
Jason Weatherald
Publication year - 2021
Publication title -
methodist debakey cardiovascular journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.552
H-Index - 23
eISSN - 1947-6094
pISSN - 1947-6108
DOI - 10.14797/zkut3813
Subject(s) - medicine , lung , interstitial lung disease , pulmonary hypertension , copd , intensive care medicine , hypoxia (environmental) , obstructive lung disease , parenchyma , lung disease , disease , pathology , chemistry , organic chemistry , oxygen
Pulmonary hypertension (PH) is a known complication of chronic parenchymal lung diseases, including chronic obstructive lung disease, interstitial lung diseases, and more rare parenchymal lung diseases. Together, these diseases encompass two of the five clinical classifications of PH: group 3 (chronic lung disease [CLD] and/or hypoxia) and group 5 (unclear and/or multifactorial mechanisms). The principal management strategy in PH associated with CLD is optimization of the underlying lung disease. There has been increasing interest in therapies that treat pulmonary arterial hypertension (group 1, PAH), and although some studies have explored the use of these oral PAH-targeted therapies to treat PH associated with CLD, there is currently no evidence to support their routine use; in fact, some studies suggest harm. Inhaled therapies that target the pulmonary vasculature may avoid certain problems observed with oral PAH therapies. Recent studies suggest a promising role for inhaled PAH therapies in group 3 PH, but this requires further study. The objective of this article is to review the current treatment strategies for group 3 and group 5 PH.